Safety and efficacy of EsoFLIP dilation in patients with esophageal dysmotility: a systematic review
Diseases of the Esophagus · 31.07.2024 · 37 (8)
DOI: 10.1093/dote/doae036 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diseases of the Esophagus, online erschienen am 24.04.2024. Verfasst von Umair Iqbal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Wellspan York Hospital, York, PA, USA. Hauptthemen laut MEDLINE: Esophageal Motility Disorders, Dilatation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Esophageal manometry is utilized for the evaluation and classification of esophageal motility disorders. EndoFlip has been introduced as an adjunctive test to evaluate esophagogastric junction (EGJ) distensibility. Treatment options for achalasia and EGJ outflow obstruction (EGJOO) include pneumatic dilation, myotomy, and botulinum toxin. Recently, a therapeutic 30 mm hydrostatic balloon dilator (EsoFLIP, Medtronic, Minneapolis, MN, USA) has been introduced, which uses impedance planimetry technology like EndoFlip. We performed a systematic review to evaluate the safety and efficacy of EsoFLIP in the management of esophageal motility disorders. A systematic literature search was performed with Medline, Embase, Web of science, and Cochrane library databases from inception to November 2022 to identify studies utilizing EsoFLIP for management of esophageal motility disorders. Our primary outcome was clinical success, and secondary outcomes were adverse events. Eight observational studies including 222 patients met inclusion criteria. Diagnoses included achalasia (158), EGJOO (48), post-reflux surgery dysphagia (8), and achalasia-like disorder (8). All studies used 30 mm maximum balloon dilation except one which used 25 mm. The clinical success rate was 68.7%. Follow-up duration ranged from 1 week to a mean of 5.7 months. Perforation or tear occurred in four patients. EsoFLIP is a new therapeutic option for the management of achalasia and EGJOO and appears to be effective and safe. Future comparative studies with other therapeutic modalities are needed to understand its role in the management of esophageal motility disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Wellspan York Hospital, York, PA, USA.
- Department of Gastroenterology and Hepatology, Geisinger Medical Center, Danville, PA, USA.
- Department of Gastroenterology, University of Toledo Medical Center, Toledo, OH, USA.
- Department of Medicine, Capital Health Regional Medical Center, Trenton, NJ, USA.
- Dow University of Health Sciences, Karachi, Pakistan.
- Department of University Libraries, University of Toledo Medical Center, Toledo, OH, USA.
ORCID-Profile: Michael Yodice
Zitieren
APA
Iqbal, U., Yodice, M., Ahmed, Z., Anwar, H., Arif, S. F., Lee-Smith, W. M., & Diehl, D. L. (2024). Safety and efficacy of EsoFLIP dilation in patients with esophageal dysmotility: a systematic review. Diseases of the Esophagus, 37(8). https://doi.org/10.1093/dote/doae036
Vancouver
Iqbal U, Yodice M, Ahmed Z, Anwar H, Arif SF, Lee-Smith WM, et al. Safety and efficacy of EsoFLIP dilation in patients with esophageal dysmotility: a systematic review. Diseases of the Esophagus. 2024;37(8). doi:10.1093/dote/doae036
BibTeX
@article{Iqbal2024,
author = {Iqbal, Umair and Yodice, Michael and Ahmed, Zohaib and Anwar, Hafsa and Arif, Syeda Faiza and Lee-Smith, Wade M and Diehl, David L},
title = {Safety and efficacy of EsoFLIP dilation in patients with esophageal dysmotility: a systematic review},
journal = {Diseases of the Esophagus},
year = {2024},
volume = {37},
number = {8},
doi = {10.1093/dote/doae036}
}
EUVIMED